ME 23andMe Holding Co. Forward P/E Multiple

The potential of 23andMe Holding Co. (ME) is based on the commercialization of biodata through pharma partnerships and the demand for DNA tests. The projected valuation based on the company's P/E ratio visualizes these expectations, with the metric holding around 0.00. However, the current chart is clouded by a critical crisis: cyberattacks, a collapse in subscriptions, and the threat of bankruptcy create extreme risks of the shares being delisted from the exchange.
Analytical breakdowns for 23andMe Holding Co.

The forward P/E ratio relates the current share price to expected earnings, allowing for an assessment of the premium paid for the business's future income. By analyzing changes in the forward price-to-earnings multiple of 23andMe Holding Co. (ME), an investor can observe the market's reaction to operational reports, which in the case of 23andMe Holding Co. (ME) reflects the critical risk of bankruptcy and delisting amid the collapse of its subscription model and the aftermath of cyberattacks.